TABLE 2.
IgG anti-PRP antibody responses in adult volunteersa
| Study | Vaccine group | Geometric mean of antibody concn (μg/ml)b
|
No. of volunteers with a ≥4-fold rise in seroconversionc | |
|---|---|---|---|---|
| Before vaccination (IgG [range]) | 1 mo after vaccination (IgG [range]) | |||
| 1 | A | 4.38 (1.00-21.43) | 84.64 (21.21-1009.7) | 10/10 |
| B | 3.91 (1.21-18.33) | 82.75 (5.54-1009.7) | 8/10 | |
| C | 2.95 (0.72-49.13) | 54.95 (7.82-1644.5) | 9/10 | |
| D | 5.53 (1.00-295.88) | 189.97 (13.37-1575.7) | 9/10 | |
| 2 | E | 7.03 (2.69-39.89) | 159.17 (33.86-1475.1) | 9/10 |
| F | 4.66 (1.16-12.07) | 134.29 (12.19-941.33) | 10/10 | |
| G | 5.47 (0.98-21.98) | 101.49 (14.21-1239.1) | 9/10 | |
| H | 3.86 (0.90-22.90) | 56.83 (7.83-163.91) | 9/10 | |
a
Each group consisted of 10 human adult volunteers. Groups C and E received the control vaccine Vaxem-Hib. All other groups received the vaccine under study.
b
There is no significant difference between the IgG geometric mean antibody concentrations for the groups (P > 0.05).
c
There is no significant difference between the groups regarding the numbers of volunteers responding with a ≥4-fold rise (P > 0.05).